Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Thyroid : Official Journal of the American Thyroid Association
|
August 26, 2018
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Yongkun Sun, Feng Du, Ming Gao, et al.
BMC Cancer
|
June 27, 2023
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial
Wen Zhang, Haitao Zhou, Jun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Wen Zhang, Caifeng Gong, Xuenan Peng, et al.
Therapeutic Advances in Medical Oncology
|
December 30, 2025
Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs
Caifeng Gong, Jinglong Huang, Dandan Cao, et al.
Journal for Immunotherapy of Cancer
|
January 29, 2026
PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy
Caifeng Gong, Shuhui You, Qi Zhang, et al.
Hepatology (Baltimore, Md.)
|
May 1, 2022
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
Jun Zhou, Yongkun Sun, Wen Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 8, 2024
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
Zhichao Jiang, Yibin Xie, Wen Zhang, et al.
BMJ Open
|
June 3, 2019
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China
Shiyu Jiang, Peng Liu, Sheng Yang, et al.
Liver Cancer
|
April 21, 2025
Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update
Xinyu Bi, Haitao Zhao, Hong Zhao, et al.
Clinical and Translational Radiation Oncology
|
March 1, 2024
Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma
Zhuanbo Yang, Liming Wang, Yirui Zhai, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Thyroid : Official Journal of the American Thyroid Association
|
August 26, 2018
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Yongkun Sun, Feng Du, Ming Gao, et al.
BMC Cancer
|
June 27, 2023
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial
Wen Zhang, Haitao Zhou, Jun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Wen Zhang, Caifeng Gong, Xuenan Peng, et al.
Therapeutic Advances in Medical Oncology
|
December 30, 2025
Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs
Caifeng Gong, Jinglong Huang, Dandan Cao, et al.
Journal for Immunotherapy of Cancer
|
January 29, 2026
PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy
Caifeng Gong, Shuhui You, Qi Zhang, et al.
Hepatology (Baltimore, Md.)
|
May 1, 2022
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
Jun Zhou, Yongkun Sun, Wen Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 8, 2024
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
Zhichao Jiang, Yibin Xie, Wen Zhang, et al.
BMJ Open
|
June 3, 2019
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China
Shiyu Jiang, Peng Liu, Sheng Yang, et al.
Liver Cancer
|
April 21, 2025
Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update
Xinyu Bi, Haitao Zhao, Hong Zhao, et al.
Clinical and Translational Radiation Oncology
|
March 1, 2024
Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma
Zhuanbo Yang, Liming Wang, Yirui Zhai, et al.
Page
of 8